|
|
Blood, 1 March 2008, Vol. 111, No. 5, pp. 2521-2526.
Prepublished online as a Blood First Edition Paper on September 27, 2007; DOI 10.1182/blood-2007-08-104984.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner1,
Adam Gondos1, and
Dianne Pulte1,2
1 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; and
2 Weill Cornell Medical Center, New York, NY
In the past, most patients with multiple myeloma (MM) died within 5 to 10 years after diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem-cell transplantation, thalidomide, lenalidomide, and bortezomib. We estimated trends in age-specific 5- and 10-year relative survival of patients with MM in the United States from 1990-1992 to 2002-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Techniques of period analysis were used to show most recent developments. Overall, 5-year relative survival increased from 28.8% to 34.7% (P < .001), and 10-year relative survival increased from 11.1% to 17.4% (P < .001) between 1990-1992 and 2002-2004. Much stronger increases were seen in the age group younger than 50 years, leading to 5- and 10-year relative survival of 56.7% and 41.3% in 2002-2004, and in the age group 50 to 59 years, leading to 5- and 10-year relative survival of 48.2% and 28.6% in 200-2004. By contrast, only moderate improvement was seen in the age group 60 to 69 years, and essentially no improvement was achieved among older patients. Our period analysis discloses a major increase in long-term survival of younger patients with MM in recent years, which most likely reflects the effect of recent advances in therapy and their dissemination in clinical practice.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
The road to cure in multiple myeloma
- Irene M. Ghobrial and Kenneth C. Anderson
Blood 2008 111: 2503.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. Hulin, T. Facon, P. Rodon, B. Pegourie, L. Benboubker, C. Doyen, M. Dib, G. Guillerm, B. Salles, J.-P. Eschard, et al.
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
J. Clin. Oncol.,
August 1, 2009;
27(22):
3664 - 3670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc.,
August 1, 2009;
20(8):
1303 - 1317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y. Kristinsson, A. R. Derolf, G. Edgren, P. W. Dickman, and M. Bjorkholm
Socioeconomic Differences in Patient Survival Are Increasing for Acute Myeloid Leukemia and Multiple Myeloma in Sweden
J. Clin. Oncol.,
April 20, 2009;
27(12):
2073 - 2080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Blade and L. Rosinol
Changing paradigms in the treatment of multiple myeloma
Haematologica,
February 1, 2009;
94(2):
163 - 166.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Brenner, A. Gondos, and D. Pulte
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Haematologica,
February 1, 2009;
94(2):
270 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ludwig, B. G. M. Durie, V. Bolejack, I. Turesson, R. A. Kyle, J. Blade, R. Fonseca, M. Dimopoulos, K. Shimizu, J. San Miguel, et al.
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Blood,
April 15, 2008;
111(8):
4039 - 4047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
